/SERA

SERA Stock - Sera Prognostics, Inc.

Q: What is the analyst price target for SERA?

Analyst price target information is not currently available for SERA.

Q: What is SERA's market cap?

Market capitalization information is not currently available for SERA.

Healthcare|Medical - Diagnostics & Research|NASDAQ

$3.55-0.56%

$0.02 (-0.56%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

100

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+40.8%upside

Target: $5.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for SERA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.98

52W High$9.13

52W Low$1.37

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$77,000	$306,000	$268,000	$82,000	$25,000
Gross Profit	$-5,000	$96,000	$75,000	$45,000	$14,000
Gross Margin	-6.5%	31.4%	28.0%	54.9%	56.0%
Operating Income	$-36,635,000	$-39,821,000	$-45,652,000	$-35,395,000	$-17,971,000
Net Income	$-32,898,000	$-36,242,000	$-44,186,000	$-35,009,000	$-19,848,000
Net Margin	-42724.7%	-11843.8%	-16487.3%	-42693.9%	-79392.0%
EPS	$-0.99	$-1.16	$-1.43	$-1.18	$-1.19

Company Overview

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

100%

Hold / Neutral

Sell / Underperform

Analyst Consensus🟢 Bullish

1 Bullish0 Neutral/Bearish

Price Targets

Average Target

↑ 40.8% Upside

Now

Low

Average

High

Based on 1 analyst

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
December 15th 2025	Jefferies	Initiation	Buy	$5

Earnings History & Surprises

SERA

Beat Rate

44%

Last 18 quarters

Avg Surprise

-10.8%

EPS vs Estimate

Beats / Misses

8/8

2 met exactly

Latest EPS

$-0.16

Q4 2025

EPS Surprise History

Q1 24

0.0%

$-0.25vs$-0.25

Q2 24

-8.7%

$-0.25vs$-0.23

Q3 24

-8.7%

$-0.25vs$-0.23

Q4 24

-9.1%

$-0.24vs$-0.22

Q1 25

-8.7%

$-0.25vs$-0.23

Q2 25

+16.7%

$-0.20vs$-0.24

Q3 25

+23.8%

$-0.16vs$-0.21

Q4 25

+15.8%

$-0.16vs$-0.19

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 18, 2026	$-0.17	—	—	—
Q4 2025	Nov 13, 2025	$-0.19	$-0.16	+15.8%	✓ BEAT
Q3 2025	Aug 6, 2025	$-0.21	$-0.16	+23.8%	✓ BEAT
Q2 2025	May 7, 2025	$-0.24	$-0.20	+16.7%	✓ BEAT
Q1 2025	Mar 19, 2025	$-0.23	$-0.25	-8.7%	✗ MISS
Q4 2024	Nov 6, 2024	$-0.22	$-0.24	-9.1%	✗ MISS
Q3 2024	Aug 7, 2024	$-0.23	$-0.25	-8.7%	✗ MISS
Q2 2024	May 8, 2024	$-0.23	$-0.25	-8.7%	✗ MISS
Q1 2024	Mar 20, 2024	$-0.25	$-0.25	0.0%	= MET
Q4 2023	Nov 8, 2023	$-0.30	$-0.23	+23.3%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.34	$-0.34	0.0%	= MET
Q2 2023	May 10, 2023	$-0.35	$-0.34	+2.9%	✓ BEAT
Q1 2023	Mar 22, 2023	$-0.42	$-0.31	+26.2%	✓ BEAT
Q4 2022	Nov 9, 2022	$-0.40	$-0.35	+12.5%	✓ BEAT
Q3 2022	Aug 10, 2022	$-0.40	$-0.37	+7.5%	✓ BEAT
Q2 2022	May 10, 2022	$-0.34	$-0.40	-17.6%	✗ MISS
Q1 2022	Mar 29, 2022	$-0.29	$-0.41	-41.4%	✗ MISS
Q4 2021	Nov 9, 2021	$-0.22	$-0.39	-77.3%	✗ MISS
Q3 2021	Aug 30, 2021	$-1.26	$-3.17	-151.6%	✗ MISS
Q3 2021	Jul 16, 2021	—	$-0.21	—	—

Frequently Asked Questions about SERA

What is SERA's current stock price?

Sera Prognostics, Inc. (SERA) is currently trading at $3.55 per share. The stock has moved -0.56% today.

What is the analyst price target for SERA?

The average analyst price target for SERA is $5.00, based on 1 analyst.

What sector is Sera Prognostics, Inc. in?

Sera Prognostics, Inc. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.

What is SERA's market cap?

Sera Prognostics, Inc. has a market capitalization of $0.13 billion, making it a small-cap company.

Does SERA pay dividends?

No, Sera Prognostics, Inc. does not currently pay a dividend to shareholders.